Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

1.4K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Spontaneous and Induced Mutations01:30

Spontaneous and Induced Mutations

323
Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).
323
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of coronary artery calcium scores on cardiovascular risk and preventive therapies: A systematic review and meta-analysis.

Global cardiology science & practice·2026
Same author

Cytomegalovirus as a potential trigger for acute coronary syndrome: A case of NSTEMI in a previously healthy patient.

Global cardiology science & practice·2026
Same author

Sedation, Sleep, and Sudden Death: How ICU Sedation Alters Cardiac Rhythmicity and Autonomic Tone.

Cardiology in review·2026
Same author

The Impact of Different Antidiabetic Drugs on Fracture Risk in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials With a Focus on SGLT2 Inhibitors.

American journal of medicine open·2025
Same author

Electromechanical Uncoupling in Critical Illness: Arrhythmia Mechanisms During ECMO and Ventricular Assist Device Support.

Cardiology in review·2025
Same author

Dissecting the difference: Left ventricular aneurysm versus pseudoaneurysm.

Global cardiology science & practice·2025

Related Experiment Video

Updated: Oct 16, 2025

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

8.4K

JAK2 and TET2 Mutation in Polycythemia Vera.

Jaskamal Padda1, Khizer Khalid1, Jayant Yadav1

  • 1Internal Medicine, JC Medical Center, Orlando, USA.

Cureus
|October 18, 2021
PubMed
Summary

Mutations in the Ten-Eleven Translocation-2 (TET2) gene are linked to hematological malignancies like myeloproliferative neoplasms (MPNs). Understanding TET2 gene function in Polycythemia Vera (PV) is crucial for improved patient care.

Keywords:
jak2myeloproliferative neoplasmspolycythemia verastat5tet2

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.9K

Related Experiment Videos

Last Updated: Oct 16, 2025

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

8.4K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.9K

Area of Science:

  • Genetics
  • Hematology
  • Oncology

Background:

  • The Ten-Eleven Translocation-2 (TET2) gene, located on chromosome 4q24, is frequently mutated in hematological malignancies.
  • TET2 mutations are observed in approximately 15% of myeloproliferative neoplasms (MPNs), a group of blood cancers.
  • Inactivation of TET2 disrupts hematopoiesis, leading to the development of hematological malignancies.

Purpose of the Study:

  • To investigate the role and significance of TET2 gene mutations in patients diagnosed with Polycythemia Vera (PV).
  • To enhance the understanding of TET2 gene function in the context of PV pathogenesis and prognosis.
  • To provide insights that can improve the management and care strategies for PV patients with TET2 alterations.

Main Methods:

  • Review of existing literature and studies focusing on TET2 gene mutations in myeloid malignancies.
  • Analysis of data linking TET2 gene function to key signaling pathways such as JAK2/STAT5.
  • Examination of TET2's role in modulating epigenetic modifications within genomic DNA.

Main Results:

  • TET2 gene mutations are associated with various myeloid malignancies, including MPNs.
  • TET2 plays a role in regulating hematopoiesis and is implicated in Polycythemia Vera (PV).
  • TET2 influences the Janus kinase-2 (JAK2) and signal transducer and activator of transcription 5 (STAT5) pathways.

Conclusions:

  • Further research into TET2 mutations in PV is essential for a comprehensive understanding of the disease.
  • Elucidating the function of TET2 in PV can lead to improved diagnostic and therapeutic approaches.
  • Understanding TET2's role in disease processes and prognoses is key to advancing patient management in hematological malignancies.